SCHEMBL12409201

SCHEMBL12409201

CC(CCNC(=O)c1ccc(O)c(C(F)(F)F)c1)COc1ccc(Cl)cc1C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 4/20 0.43
MAPK1 P28482 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 5/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MRGPRX4 Q96LA9 1/20 0.39
DDR1 Q08345 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GAA P10253 1/20 0.39
RBP4 P02753 1/20 0.39
SLC6A3 Q01959 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409197 0.90 ESRRG (0.47) KDM4EALDH1A1MAPK1TDP1LMNA
SCHEMBL12409199 0.85 KDM4E (0.53) KDM4EALDH1A1MAPK1TDP1LMNA
SCHEMBL12409204 0.85 KDM4E (0.52) KDM4EALDH1A1MAPK1TDP1LMNA
SCHEMBL12409195 0.80 PTGER1 (0.43) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL12409196 0.74 KDM4E (0.53) KDM4EALDH1A1MAPK1TDP1LMNA
SCHEMBL12966728 0.71 EPHX2 (0.49) ALDH1A1LMNASMN1; SMN2SLC6A3RAB9A
SCHEMBL2173939 0.68 KDM4E (0.61) KDM4EALDH1A1MAPK1TDP1LMNA
SCHEMBL12967979 0.67 MRGPRX4 (0.44) KDM4EALDH1A1MAPK1TDP1LMNA
SCHEMBL278403 0.67 LMNA (0.54) KDM4EALDH1A1MAPK1TDP1LMNA
SCHEMBL12409218 0.66 SERPINE1 (0.42) KDM4EALDH1A1MAPK1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973079-B2 Methods and compounds for treating retinol-related diseases REVISION THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-7973079-B2 Methods and compounds for treating retinol-related diseases REVISION THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-20090088435-A1 METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2009-04-02 US disclosed
US-20090088435-A1 METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088435-A1 METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES RBP1, RBP4, ALDH1A2 KDM4E 4096/4885ALDH1A1 40/4885MAPK1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.